These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1982901)

  • 21. Late life schizophrenia and its treatment: pharmacologic issues in older schizophrenic patients.
    Tran-Johnson TK; Krull AJ; Jeste DV
    Clin Geriatr Med; 1992 May; 8(2):401-10. PubMed ID: 1350940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bodily reactions to people and events in schizophrenics.
    Tarrier N; Vaughn C; Lader MH; Leff JP
    Arch Gen Psychiatry; 1979 Mar; 36(3):311-5. PubMed ID: 33634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of neuroleptics in a attempt at understanding the vulnerability to schizophrenia].
    Meurice E
    Acta Psychiatr Belg; 1992; 92(6):339-54. PubMed ID: 1364282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Test-retest stability of the oral niacin test and electrodermal activity in patients with schizophrenia.
    Nilsson BM; Hultman CM; Ekselius L
    Prostaglandins Leukot Essent Fatty Acids; 2009; 81(5-6):367-72. PubMed ID: 19864122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics.
    Spohn HE; Coyne L; Lacoursiere R; Mazur D; Hayes K
    Arch Gen Psychiatry; 1985 Sep; 42(9):849-59. PubMed ID: 2864028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrodermal activity in antidepressant medicated and unmedicated depressive patients and in matched healthy subjects.
    Thorell LH; Kjellman BF; d'Elia G
    Acta Psychiatr Scand; 1987 Dec; 76(6):684-92. PubMed ID: 3442260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin conductance nonresponding and nonhabituation in schizophrenic patients.
    Bartfai A; Levander SE; Nybäck H; Schalling D
    Acta Psychiatr Scand; 1987 Mar; 75(3):321-9. PubMed ID: 2884808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relations between two-flash discrimination and electrodermal activity, re-examined in schizophrenics and normals.
    Gruzelier JH; Venables PH
    J Psychiatr Res; 1975 Aug; 12(2):73-85. PubMed ID: 240021
    [No Abstract]   [Full Text] [Related]  

  • 29. [Neuroleptics, atypical antipsychotics and "awakening"].
    Murawiec S
    Psychiatr Pol; 2000; 34(5):741-50. PubMed ID: 11202016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A limiting factor in the "normalization" of schizophrenic orienting response dysfunction.
    Bernstein AS; Riedel JA; Pava J; Schnur D; Lubowsky J
    Schizophr Bull; 1985; 11(2):230-54. PubMed ID: 2861655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Schizophrenic psychoses: distinct therapeutic advantages of atypical neuroleptics. Serdolect is effective and free of side effects].
    Psychiatr Prax; 1998 Sep; 25(5 Suppl):1-4. PubMed ID: 9802117
    [No Abstract]   [Full Text] [Related]  

  • 32. Comments on paper, "Psychophysiological patterns of response in schizophrenia".
    Venables PH
    J Nerv Ment Dis; 1974 Feb; 158(2):115-7. PubMed ID: 4149887
    [No Abstract]   [Full Text] [Related]  

  • 33. Do schizophrenic patients show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion?
    Kring AM; Neale JM
    J Abnorm Psychol; 1996 May; 105(2):249-57. PubMed ID: 8723006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response time and electrodermal measures in chronic schizophrenia: the effects of chlorpromazine.
    Pugh LA
    J Nerv Ment Dis; 1968 Jan; 146(1):62-70. PubMed ID: 5648860
    [No Abstract]   [Full Text] [Related]  

  • 35. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic, pharmacologic, and psychosocial factors influencing response to neuroleptics.
    Kane JM
    Psychopharmacol Bull; 1992; 28(3):227-9. PubMed ID: 1362275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of neuroleptics on the frontal functions of schizophrenics].
    Verdoux H; Magnin E; Bourgeois M
    Ann Med Psychol (Paris); 1994 Oct; 152(8):530-4. PubMed ID: 7818228
    [No Abstract]   [Full Text] [Related]  

  • 38. [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
    Briken P; Nika E; Krausz M; Naber D
    Fortschr Neurol Psychiatr; 2002 Mar; 70(3):139-44. PubMed ID: 11880946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrodermal anomalies in recent-onset schizophrenia: relationships to symptoms and prognosis.
    Dawson ME; Nuechterlein KH; Schell AM
    Schizophr Bull; 1992; 18(2):295-311. PubMed ID: 1621075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commentary on: "Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia." Psychopharmacology (1980) 72:17-19.
    Angrist B; Rotrosen J; Gershon S
    Psychopharmacology (Berl); 2001 Nov; 158(3):219-21. PubMed ID: 11713609
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.